OSferionBiomaterials

OSferionBiomaterials is a Japan-based orthopedic biomaterials and medical device company focused on research, development, manufacturing, and sales of artificial bone substitutes, metal implants, and related surgical products. Its flagship product family is OSferion, a beta-tricalcium phosphate bone void filler and artificial bone material used in orthopedic applications where the scaffold is resorbed and replaced by bone during healing. The company also markets orthopedic implants such as the TriS plate systems and products for cervical laminoplasty and knee preservation procedures. Historically formed as Olympus Biomaterial and later renamed Olympus Terumo Biomaterials, the company became part of Polaris Capital Group in 2024 and changed its name to OSferionBiomaterials in August 2025. The business is commercial-stage and centered on orthopedic reconstruction and function-preserving surgery rather than therapeutic drug development.